Department of Internal Medicine, Division of Pulmonary/Critical Care Medicine, University of California, Davis, California 95616, USA.
J Cyst Fibros. 2010 Mar;9(2):84-92. doi: 10.1016/j.jcf.2009.10.001. Epub 2010 Jan 15.
Decreased expired nitric oxide (eNO) is commonly observed in cystic fibrosis (CF) patients and is usually explained by dysregulation of NO synthase (NOS) isoforms in respiratory tract epithelium. Later stages of this disease are accompanied by intense airway infiltration of phagocytes with high NOS activity, abundant levels of the hemoprotein myeloperoxidase (MPO) and significant production of significant reactive oxygen species.
This study characterizes the contribution of the high airway levels of MPO to decreased eNO levels in adult CF patients. NO metabolites (NO(x)) and MPO levels in fresh sputum of control and adult CF patients were determined and related to measurements of eNO and to in vitro consumption of NO in CF sputum.
Despite essentially equal levels of NO(x) in sputum, eNO was 2- to 3-fold lower in CF patients compared to healthy controls. In CF patients, eNO levels were negatively associated with sputum peroxidase activity. In vivo correlations were confirmed by ex vivo studies of NO consumption by MPO in CF sputum. Immunodepletion studies confirmed MPO as the major heme peroxidase in CF sputum contributing to the hydrogen peroxide (H(2)O(2))-dependent consumption of NO.
In CF airways MPO acts as a phagocyte-derived NO oxidase that diminishes NO bioavailability at airway surfaces, possibly identifying this peroxidase as a potential target for therapeutic intervention.
囊性纤维化 (CF) 患者中通常观察到呼出的一氧化氮 (eNO) 减少,这通常归因于呼吸道上皮细胞中一氧化氮合酶 (NOS) 同工型的失调。该疾病的后期阶段伴有吞噬细胞在气道中的强烈浸润,这些吞噬细胞具有高 NOS 活性、大量血红素过氧化物酶 (MPO) 和大量产生的活性氧。
本研究旨在表征气道中高水平 MPO 对成年 CF 患者 eNO 水平降低的贡献。测定对照和成年 CF 患者新鲜痰中的 NO 代谢物 (NO(x)) 和 MPO 水平,并与 eNO 测量值和 CF 痰中 NO 的体外消耗相关。
尽管痰中的 NO(x) 水平基本相等,但 CF 患者的 eNO 比健康对照组低 2-3 倍。在 CF 患者中,eNO 水平与痰中过氧化物酶活性呈负相关。体内相关性通过 CF 痰中 MPO 对 NO 消耗的体外研究得到证实。免疫耗竭研究证实 MPO 是 CF 痰中主要的血红素过氧化物酶,它可导致气道表面 NO 生物利用度降低,这可能表明该过氧化物酶是潜在的治疗干预靶点。
在 CF 气道中,MPO 作为一种吞噬细胞衍生的 NO 氧化酶,降低了气道表面的 NO 生物利用度,可能将这种过氧化物酶确定为潜在的治疗干预靶点。